CRINETICS PHARMACEUTICALS IN's ticker is CRNX and the CUSIP is 22663K107. A total of 139 filers reported holding CRINETICS PHARMACEUTICALS IN in Q2 2023. The put-call ratio across all filers is 19.18 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $14,247,036 | +65.0% | 479,053 | 0.0% | 3.80% | +118.8% |
| Q2 2023 | $8,632,535 | +49.1% | 479,053 | +32.9% | 1.74% | +15.6% |
| Q1 2023 | $5,787,896 | -14.9% | 360,392 | -3.0% | 1.50% | -14.7% |
| Q4 2022 | $6,800,994 | -5.1% | 371,639 | +1.9% | 1.76% | +4.0% |
| Q3 2022 | $7,163,000 | +4.7% | 364,710 | -0.5% | 1.70% | -10.7% |
| Q2 2022 | $6,839,000 | -15.0% | 366,676 | 0.0% | 1.90% | -12.0% |
| Q1 2022 | $8,049,000 | -25.4% | 366,676 | -3.5% | 2.16% | +9.8% |
| Q4 2021 | $10,790,000 | +71.8% | 379,792 | +27.3% | 1.97% | +102.0% |
| Q3 2021 | $6,281,000 | – | 298,392 | – | 0.97% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Saturn V Capital Management LP | 1,126,579 | $33,504,459 | 14.02% |
| New Leaf Venture Partners, L.L.C. | 141,000 | $4,193,340 | 5.38% |
| First Light Asset Management, LLC | 1,583,329 | $47,088,204 | 4.47% |
| Paradigm Biocapital Advisors LP | 2,178,737 | $64,795,638 | 4.40% |
| Bain Capital Life Sciences Investors, LLC | 1,275,552 | $37,934,916 | 4.24% |
| Altium Capital Management LP | 262,000 | $7,791,880 | 4.06% |
| 5AM Venture Management, LLC | 462,286 | $13,748,386 | 3.96% |
| MPM BioImpact LLC | 479,053 | $14,247,036 | 3.80% |
| Affinity Asset Advisors, LLC | 450,000 | $13,383,000 | 3.76% |
| Opaleye Management Inc. | 370,000 | $11,003,800 | 3.58% |